Description
Inulin is an investigational drug currently being studied in clinical trials for metastatic colorectal cancer (CRC). It is a type of soluble fiber derived from plants. In the NCT06347198 trial, it is being tested in combination with two other drugs, fruquintinib and sintilimab, as a potential treatment option for patients whose cancer has progressed after previous therapies (third-line or later). The trial is exploring whether adding inulin to this combination can improve outcomes. The study is in an early phase (Phase 1), meaning it is primarily focused on determining the safety and tolerability of the combination and getting initial signals of effectiveness. The trial is recruiting patients with microsatellite stable (MSS) tumors. It is important to note that inulin is not yet an approved treatment for CRC and is still under investigation.
Mechanism of Action
Inulin is a type of prebiotic fiber. In the context of this trial, the specific mechanism by which inulin might affect cancer is being investigated. Prebiotics can influence the gut microbiome, which may have effects on the immune system and potentially tumor growth or response to other therapies. However, the exact way inulin is expected to work in this combination therapy is not fully established and is part of the research being conducted in the clinical trial.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.